1. Jaros PA, DeLuise VP. Pingueculae and pterygia. Surv Ophthalmol. 1988; 33:41–9.
Article
2. Austin P, Jakobiec FA, Iwamoto T. Elastodysplasia and elastodystrophy as the pathologic bases of ocular pterygia and pingueculae. Ophthalmology. 1983; 90:96–109.
3. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984; 98:225–8.
Article
4. Wong WW. A hypothesis on the pathogenesis of pterygium. Ann Ophthalmol. 1978; 10:303–8.
5. Frucht-Pery J, Siganos CS, Solomon A, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol. 1999; 127:148–52.
Article
6. Tarr KH, Constable IJ. Late complications of pterygium treatment. Br J Opthalmol. 1980; 64:496–505.
Article
7. Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Opthalmology. 1992; 99:1647–54.
Article
8. Oum BS, Lee JS. The effect of mitomycin C on inhibition of cellular proliferation and type-1 collagen, Laminin synthesis of pterygium mesenchymal cell. J Korean Opthalmol Soc. 1999; 40:712–20.
9. Willems EW, Nooter K, Verweij J. Antitumor antibiotics. In: Chabner BA, Longo DL eds. Cancer chemotherapy & biotherapy: principles and practice. 4th ed.Philadelphia: Lippincott Williams & Wilkins;2006. 1:chap. 16.
10. Kim JH, Lee HB, Yoon DK. Scleral grafts for the cases of sclera perforation, sclera ectasia and sclera necrosis. J Korean Ophthalmol Soc. 1978; 19:55–61.
11. Song HY, Im JS, Kwak JY. Acellular dermal allograft transplantation in patients with scleromalacia after pterygium excision. J Korean Opthalmol Soc. 2008; 49:1685–9.
Article
12. Na YS, Joo MJ, Kim JH. Results of sclera allograftind on sclera necrosis following pterygium excision. J Korean Opthalmol Soc. 2005; 46:402–9.
13. Wan norliza WM, Raihan IS, Azwa JA, Ibrahim M. Scleral melting 16 years after pterygium excision with topical mitomycin C adjuvant therapy. Cont Lens Anterior Eye. 2006; 29:165–7.
Article
14. Anduze AL, Burnett JM. Indications for and complications of mitomycin-C in pterygium surgery. Ophthalmic Surg Lasers. 1996; 27:667–73.
Article
15. Brooks AM, Robertson IF, Mahoney AM. Ocular rigidity and intraocular pressure in keratoconus. Aust J Ophthalmol. 1984; 12:317–24.
Article
16. Nessim M, Kyprianou I, Kumar V, Murray PI. Anterior scleritis, scleral thinning, and intraocular pressure measurement. Ocul Immunol Inflamm. 2005; 13:455–7.
Article
17. Jorgensen JS, Guthoff R. The role of episcleral venous pressure in the development of secondary glaucoma. Klin Monatsbl Augenheilkd. 1988; 193:471–5.
18. Ruiz-Ederra J, Verkman AS. Mouse model of sustained elevation in intraocular pressure produced by episcleral vein occlusion. Exp Eye Res. 2006; 82:879–84.
Article
19. Danias J, Shen F, Kavalarakis M, et al. Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp Eye Res. 2006; 82:219–28.
Article
20. Mittag TW, Danias J, Pohorenec G, et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2000; 41:3451–9.
21. Urcola JH, Hernández M, Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res. 2006; 83:429–37.
Article
22. Shareef SR, Garcia-Valenzuela E, Salierno A, et al. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res. 1995; 61:379–82.
Article